Fresenius stock holds steady after latest earnings, Xetra quote in focus

Published on 09/01/2026 at 18:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock is trading in the mid-40 EUR range on Xetra as of August 31, 2026, while investors digest the most recent quarterly figures and guidance from the German healthcare group.

Fresenius SE – Isometrischer 3D-Render: Miniatur-Klinikcampus mit Hauptgebäude, Hubschrauberlandeplatz, Parkplatz — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Miniatur-Klinikcampus mit Hauptgebäude, Hubschrauberlandeplatz, Parkplatz, Illustration mit AI erstellt.

Fresenius SE (ISIN DE0005785604) stock closed at EUR 45.245 on Xetra on August 31, 2026, putting the German healthcare group in the mid-40 EUR range ahead of the September 1, 2026 session.

Latest price and trading snapshot

According to a consolidated European equities overview dated August 31, 2026, Fresenius shares traded between EUR 45.245 and EUR 46.000 during the latest completed Xetra session.

The same data set shows a closing level of EUR 45.245, representing a day loss of 1.33 percent and a decline of 0.610 points from the prior reference level, on trading volume of 1.04 million shares as of August 31, 2026.

Recent earnings context and investor focus

Investors looking at Fresenius stock in early September 2026 are primarily weighing the latest reported quarterly figures and the company’s guidance for the current fiscal year, even though detailed interim results are not explicitly broken out in the day-filtered sources.

Market participants note that the parent company and its dialysis subsidiary recorded moderate single-day declines in the final August 2026 Xetra trading session captured in the overview, which keeps attention on how earnings and cash flow will evolve over the remainder of 2026.

Go deeper

More on Fresenius stock and filings

For a broader view of Fresenius SE as an issuer and its regulatory disclosures, investors can explore additional filings and topic pages.

All news on this ISIN Investor Relations

Key healthcare operations and products

Fresenius SE is a diversified healthcare group with activities that typically include hospital operations, dialysis services, and medical technology solutions, making its revenue and earnings closely tied to patient volumes and reimbursement frameworks in Germany and international markets.

Representative products and services range from dialysis treatments and catheters to hospital care offerings, which together underpin the company’s long-term growth profile and generate recurring revenue streams across Europe and beyond.

Stock level on Xetra and investor perspective

As of August 31, 2026, Fresenius stock closed at EUR 45.245 on Xetra, after trading in a narrow intraday band between EUR 45.245 and EUR 46.000 on volume of 1.04 million shares, giving investors a reference level for the September 1, 2026 session.